ArticleAnimals : an open access journal from MDPI2026
GPR35 Mediates the Proliferation and Adipogenesis of Goat Intramuscular Preadipocytes Through the cAMP/PKA Signaling Pathway.
Article in Animals : an open access journal from MDPI, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
GPR35 is a member of the G-protein-coupled receptor family and existing studies have shown that its expression may be negatively correlated with fat deposition in mice. However, the exact role of GPR35 in goat intramuscular preadipocytes' adipogenic differentiation remains unknown. This study is the first to demonstrate that GPR35 inhibits the maturation and differentiation of goat intramuscular preadipocytes via activating the cAMP/PKA signaling pathway under in vitro culture conditions. The functional experimental results showed that GPR35 overexpression suppressed the adipogenic differentiation, lipid synthesis, and proliferation capacity of goat intramuscular preadipocytes, and concurrently downregulated the expression of adipogenic differentiation marker genes and cell proliferation marker genes. Conversely, GPR35 knockdown promoted lipid accumulation, reduced intracellular cAMP levels, and ultimately enhanced the differentiation and proliferation capacity of intramuscular preadipocytes. Treatment with the cAMP inhibitor SQ22536 and PKA phosphorylation inhibitor H89 successfully reversed the phenotypic changes induced by GPR35 overexpression, including abnormal lipid droplet morphology, decreased triglyceride (TG) content, and inhibition of the expression of genes related to adipocyte differentiation/proliferation/metabolism (such as CDK2, PCNA, and HSL). These results confirm that GPR35 mainly regulates intramuscular fat deposition in goats through the cAMP/PKA pathway, providing a new target for elucidating the molecular mechanism of lipid metabolism and goat molecular breeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.